Trial II of Lung Protection With Azithromycin in the Preterm Infant

Completed · Phase 2 · Has a placebo group

Conditions studied: Bronchopulmonary Dysplasia

In brief

The hypothesis of this study is that administration of azithromycin to ventilated premature infants will decrease the incidence and severity of BPD. The purpose of this study is to determine if Azithromycin treatment is beneficial for prevention of bronchopulmonary dysplasia in preterm infants.

Key facts

Study ID

NCT00319956

Run by

Hubert Ballard

People needed

220

Starts

2004-09-01

Expected to finish

2012-06-01

Last updated by the study team

2018-06-27

Who can join

Age: any, up to 0. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• birthweight less than 1250 grams admitted to UK NICU
• mechanical ventilation within the first 72 hours of life

You may not qualify if…

• confirmed sepsis by blood culture
• multiple congenital anomalies or known syndromes
• intrauterine growth retardation with birthweight less than 10%ile for gestational age
• ROM for >7 days

Where it is running

• University of Kentucky Medical Center — Lexington, Kentucky, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.